- Elvitegravir
drugbox
IUPAC_name = 6- [(3-Chloro-2-fluorophenyl)methyl] -1- [(2"S")-1-hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxoquinoline-3-carboxylic acid
CAS_number =
ATC_prefix =
ATC_suffix =
PubChem = 5277135
C=23 | H=23 | Cl=1 | F=1 | N=1 | O=5
molecular_weight = 447.883 g/mol
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_US =
legal_UK =
legal_US =
legal_status =
routes_of_administration =Elvitegravir (EVG) is an
investigational new drug for the treatment ofHIV infection. It acts as anintegrase inhibitor . It is undergoing Phase IIIclinical trial [Gilead Press Release [http://www.gilead.com/pr_1177855 Phase III Clinical Trial of Elvitegravir] July 22, 2008] conducted by the pharmaceutical companyGilead Sciences , which licensed EVG fromJapan Tobacco in March 2005. [Gilead Press Release [http://www.gilead.com/pr_687733 Gilead and Japan Tobacco Sign Licensing Agreement for Novel HIV Integrase Inhibitor] March 22, 2005] [cite journal |author=Shimura K, Kodama E, Sakagami Y, "et al" |title=Broad Anti-Retroviral Activity and Resistance Profile of a Novel Human Immunodeficiency Virus Integrase Inhibitor, Elvitegravir (JTK-303/GS-9137) |journal=J Virol |volume= |issue= |pages= |year=2007 |pmid=17977962 |doi=10.1128/JVI.01534-07 |url=http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=17977962] [cite journal |author=Stellbrink HJ |title=Antiviral drugs in the treatment of AIDS: what is in the pipeline ? |journal=Eur. J. Med. Res. |volume=12 |issue=9 |pages=483–95 |year=2007 |pmid=17933730 |doi=]According to the results of the phase II clinical trial, patients taking once-daily elvitegravir boosted by
ritonavir had greater reductions inviral load after 24 weeks compared to individuals randomized to receive a ritonavir-boostedprotease inhibitor . [Thaczuk, Derek and Carter, Micheal. [http://www.aidsmap.com/en/news/69FAE9A0-307D-430B-8023-DA133AD0CEDB.asp ICAAC: Best response to elvitegravir seen when used with T-20 and other active agents] Aidsmap.com. 19 Sept. 2007.]References
Wikimedia Foundation. 2010.